The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Montelukast, a Once-Daily Leukotriene Receptor Antagonist, in the Treatment of Chronic Asthma<subtitle>A Multicenter, Randomized, Double-blind Trial</subtitle>
Abstract
OBJECTIVES: To determine the clinical effect of oral montelukast sodium, a leukotriene receptor antagonist, in asthmatic patients aged 15 years or more. DESIGN: Randomized, multicenter, double-blind, placebo-controlled, parallel-group study. A 2-week, single-blind, placebo run-in period was followed by a 12-week, double-blind treatment period (montelukast sodium, 10 mg, or matching placebo, once daily at bedtime) and a 3-week, double-blind, washout period. SETTING/PATIENTS: Fifty clinical centers randomly allocated 681 patients with chronic, stable asthma to receive placebo or montelukast after demonstrating a forced expiratory volume in 1 second 50% to 85% of the predicted value, at least a 15% improvement in forced expiratory volume in 1 second (absolute value) after inhaled beta-agonist administration, a minimal predefined level of daytime asthma symptoms, and inhaled beta-agonist use. Twenty-three percent of the patients used concomitant inhaled corticosteroids. PRIMARY END POINTS: Forced expiratory volume in 1 second and daytime asthma symptoms. RESULTS: Montelukast improved airway obstruction (forced expiratory volume in 1 second, morning and evening peak expiratory flow rate) and patient-reported end points (daytime asthma symptoms, "as-needed" beta-agonist use, nocturnal awakenings) (P<.001 compared with placebo). Montelukast provided near-maximal effect in these end points within the first day of treatment. Tolerance and rebound worsening of asthma did not occur. Montelukast improved outcome end points, including asthma exacerbations, asthma control days (P<.001 compared with placebo), and decreased peripheral blood eosinophil counts (P<.001 compared with placebo). The incidence of adverse events and discontinuations from therapy were similar in the montelukast and placebo groups. CONCLUSIONS: Montelukast, compared with placebo, significantly improved asthma control during a 12-week treatment period. Montelukast was generally well tolerated, with an adverse event profile comparable with that of placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standardization of Spirometry, 1994 Update. American Thoracic Society.
(1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.3.7663792 · Cited by 6,594
Determining a minimal important change in a disease-specific quality of life questionnaire
JUNIPER, E. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90036-1 · Cited by 1,824
Juniper, E. F., Guyatt, G. H., Epstein, R. S., Ferrie, P. J., Jaeschke, R., & Hiller, T. K. (1992) · Thorax · doi:10.1136/thx.47.2.76 · Cited by 1,232
An Economic Evaluation of Asthma in the United States
Weiss, K. B., Gergen, P. J., & Hodgson, T. A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261304 · Cited by 995
Leukotriene E4 and granulocytic infiltration into asthmatic airways
Laitinen, L. A., Haahtela, T., Vilkka, V, Lee, T. H., & Spur, B. W. (1993) · The Lancet · doi:10.1016/0140-6736(93)91073-u · Cited by 526
The Effect of Inhibition of 5-Lipoxygenase by Zileuton in Mild-to-Moderate Asthma
Israel, E., Rubin, P., Kemp, J. P., Grossman, J., Pierson, W., Siegel, S. C., Tinkelman, D., Murray, J. J., Busse, W., Segal, A. T., et al. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-11-199312010-00001 · Cited by 362
Spector, S. L., Smith, L. J., & Glass, M. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.150.3.8087328 · Cited by 341
Tinkelman, D. G., Reed, C. E., Nelson, H. S., & Offord, K. P. (1993) · Pediatrics · doi:10.1542/peds.92.1.64 · Cited by 297
Israel, E. (1996) · JAMA · doi:10.1001/jama.1996.03530360041036 · Cited by 295
Effect of oral prednisone on airway inflammatory mediators in atopic asthma.
Dworski, R., Fitzgerald, G. A., Oates, J. A., & Sheller, J. R. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.149.4.8143061 · Cited by 289
Effects of Leukotriene D on the Airways in Asthma
Griffin, M. P., Weiss, J. W., Leitch, A. G., McFadden, E. R., Corey, E. J., Austen, K. F., & Drazen, J. M. (1983) · New England Journal of Medicine · doi:10.1056/nejm198302243080807 · Cited by 284
Jones, T. R., Labelle, M., Belley, M., Champion, E., Charette, L., Evans, J., Ford-Hutchinson, A. W., Gauthier, J. Y., Lord, A., Masson, P., et al. (1995) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y95-028 · Cited by 248
Mechanism of propranolol withdrawal phenomena.
Nattel, S., Rangno, R. E., & Van Loon, G. (1979) · Circulation · doi:10.1161/01.cir.59.6.1158 · Cited by 202
Noonan, M., Chervinsky, P., Brandon, M., Zhang, J., Kundu, S., McBurney, J., & Reiss, T. (1998) · European Respiratory Journal · doi:10.1183/09031936.98.11061232 · Cited by 175
Self-citationReiss, T. F., Sorkness, C. A., Stricker, W., Botto, A., Busse, W. W., Kundu, S., & Zhang, J. (1997) · Thorax · doi:10.1136/thx.52.1.45 · Cited by 161
Self-citationReiss, T. F., Altman, L. C., Chervinsky, P., Bewtra, A., Stricker, W. E., Noonana, G. P., Kundu, S., & Zhang, J. (1996) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(96)70086-6 · Cited by 160
Self-citationA placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene–receptor antagonist
Altman, L. C., Munk, Z. M., Seltzer, J. M., Noonan, N., Shingo, S., Zhang, J., & Reiss, T. F. (1998) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(98)70054-5 · Cited by 148
Self-citationMeasurement characteristics of two asthma symptom diary scales for use in clinical trials
Santanello, N., Barber, B., Reiss, T. F., Friedman, B., Juniper, E. F., & Zhang, J. (1997) · European Respiratory Journal · doi:10.1183/09031936.97.10030646 · Cited by 138
Self-citationLepeleire, I. D., Reiss, T. F., Rochette, F., Botto, A., Zhang, J., Kundu, S., & Decramer, M. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90184-3 · Cited by 105
Self-citationIn Vitro Study of beta-Adrenergic Receptors
Wolfe, B. B., Harden, T. K., & Molinoff, P. B. (1977) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.17.040177.003043 · Cited by 100
Adelroth, E. C., Inman, M. D., Summers, E., Pace, D. G., Modi, M., & O’Byrne, P. M. (1997) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(97)70098-8 · Cited by 66
Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol.
Rangno, R., & Langlois, S. (1982) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1982.tb01939.x · Cited by 60
Goldstein, R. A., Paul, W. E., Metcalfe, D. D., Busse, W. W., & Reece, E. R. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-9-199411010-00011 · Cited by 60
Wickremasinghe, R. G., Khan, M. A., & Hoffbrand, A. V. (1993) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/0952-3278(93)90099-i · Cited by 17
Cited by
Global strategy for asthma management and prevention: GINA executive summary
Bateman, E. D., Hurd, S. S., Barnes, P. J., Bousquet, J., Drazen, J. M., FitzGerald, M., Gibson, P., Ohta, K., O'Byrne, P., Pedersen, S. E., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00138707 · Cited by 3,203
Peters-Golden, M., & Henderson, W. R. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071371 · Cited by 1,013
Characterization of the human cysteinyl leukotriene CysLT1 receptor
Lynch, K. R., O'Neill, G. P., Liu, Q., Im, D.-S., Sawyer, N., Metters, K. M., Coulombe, N., Abramovitz, M., Figueroa, D. J., Zeng, Z., et al. (1999) · Nature · doi:10.1038/21658 · Cited by 965
Treatment of Asthma with Drugs Modifying the Leukotriene Pathway
Drazen, J. M., Israel, E., & O'Byrne, P. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901213400306 · Cited by 820
Inflammatory Mediators of Asthma: An Update
Barnes, P. J., Chung, K. F., & Page, C. P. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01381-4 · Cited by 717
Metadata
- Authors
- Reiss, T. F.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 1998-06-08
- Volume
- 158
- Issue
- 11
- Pages
- 1213
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W1996982788
- Cited by
- 484
- References
- 24
- FWCI
- 29.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.